Authors
Zeying Zhao, Yixian Huang, Zhaoyi Wu, Xixi Luo, Rui Liao, Chengcheng Zhang, Wei Liu, Na Jiang, Yanjiao Ou, Leida Zhang, Mengshi Yi
Published in
Clinics and research in hepatology and gastroenterology. Pages 102966. Nov 05, 2026. Epub Nov 05, 2026.
Abstract
Basiliximab has been associated with a reduced risk of acute cellular rejection, infection and renal failure in liver transplantation. However, its association with early graft dysfunction (EAD) and EAD-related outcomes remains unclear.
A multicenter retrospective cohort was enrolled. Association of basiliximab use with EAD, and EAD-related outcomes (prolonged ICU stay and peri-operative mortality) were evaluated. The treatment effects were estimated using overlap weighting method based on outcome-specific propensity score models incorporating recipient, donor and peri-operative characteristics. Sensitivity analysis was performed after excluding centers with highly imbalanced basiliximab use.
Of 903 eligible recipients, 393 (43.5%) received basiliximab induction. Overlap weighting achieved excellent covariate balance (nearly all absolute standardized mean differences < 0.03). After weighting, EAD incidence was 7.8 percentage points lower with basiliximab (23.3% vs. 31.1%); overlap-weighted logistic regression showed that basiliximab use was associated with significantly lower odds of EAD (OR, 0.67; 95% CI, 0.48-0.94; p = 0.02). No significant associations were observed with prolonged ICU stay or peri-operative mortality, and findings remained robust in sensitivity analyses.
Basiliximab induction was associated with lower odds of EAD after liver transplantation; however, as confounding by indication cannot be excluded in this observational design, validation in larger prospective studies is warranted.
PMID:
42988354
Bibliographic data and abstract were imported from PubMed on 06 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 11
- Comments 0